Initiation and use of propranolol for infantile hemangioma: Report of a consensus conference

Beth A. Drolet, Peter C. Frommelt, Sarah L. Chamlin, Anita Haggstrom, Nancy M. Bauman, Yvonne E. Chiu, Robert H. Chun, Maria C. Garzon, Kristen E. Holland, Leonardo Liberman, Susan MacLellan-Tobert, Anthony J. Mancini, Denise Metry, Katherine B. Puttgen, Marcia Seefeldt, Robert Sidbury, Kendra M. Ward, Francine Blei, Eulalia Baselga, Laura CassidyDavid H. Darrow, Shawna Joachim, Eun Kyung M Kwon, Kari Martin, Jonathan Perkins, Dawn H. Siegel, Robert J. Boucek, Ilona J. Frieden

Research output: Contribution to journalArticle

292 Citations (Scopus)

Abstract

Infantile hemangiomas (IHs) are common neoplasms composed of proliferating endothelial-like cells. Despite the relative frequency of IH and the potential severity of complications, there are currently no uniform guidelines for treatment. Although propranolol has rapidly been adopted, there is significant uncertainty and divergence of opinion regarding safety monitoring, dose escalation, and its use in PHACE syndrome (PHACE = posterior fossa, hemangioma, arterial lesions, cardiac abnormalities, eye abnormalities; a cutaneous neurovascular syndrome characterized by large, segmental hemangiomas of the head and neck along with congenital anomalies of the brain, heart, eyes and/or chest wall). A consensus conference was held on December 9, 2011. The multidisciplinary team reviewed existing data on the pharmacologic properties of propranolol and all published reports pertaining to the use of propranolol in pediatric patients. Workgroups were assigned specific topics to propose protocols on the following subjects: contraindications, special populations, pretreatment evaluation, dose escalation, and monitoring. Consensus protocols were recorded during the meeting and refined after the meeting. When appropriate, protocol clarifications and revision were made and agreed upon by the group via teleconference. Because of the absence of high-quality clinical research data, evidence-based recommendations are not possible at present. However, the team agreed on a number of recommendations that arose from a review of existing evidence, including when to treat complicated IH; contraindications and pretreatment evaluation protocols; propranolol use in PHACE syndrome; formulation, target dose, and frequency of propranolol; initiation of propranolol in infants; cardiovascular monitoring; ongoing monitoring; and prevention of hypoglycemia. Where there was considerable controversy, the more conservative approach was selected. We acknowledge that the recommendations are conservative in nature and anticipate that they will be revised as more data are made available.

Original languageEnglish
Pages (from-to)128-140
Number of pages13
JournalPediatrics
Volume131
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Hemangioma
Propranolol
Eye Abnormalities
Telecommunications
Thoracic Wall
Hypoglycemia
Uncertainty
Consensus Conference
Monitoring
Neck
Endothelial Cells
Head
Guidelines
Pediatrics
Safety
Dose
Syndrome
Skin
Brain
Research

Keywords

  • Bradycardia
  • Hypertension
  • Hypoglycemia
  • Infantile hemangioma
  • PHACE syndrome
  • Propranolol

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Arts and Humanities (miscellaneous)

Cite this

Drolet, B. A., Frommelt, P. C., Chamlin, S. L., Haggstrom, A., Bauman, N. M., Chiu, Y. E., ... Frieden, I. J. (2013). Initiation and use of propranolol for infantile hemangioma: Report of a consensus conference. Pediatrics, 131(1), 128-140. https://doi.org/10.1542/peds.2012-1691

Initiation and use of propranolol for infantile hemangioma : Report of a consensus conference. / Drolet, Beth A.; Frommelt, Peter C.; Chamlin, Sarah L.; Haggstrom, Anita; Bauman, Nancy M.; Chiu, Yvonne E.; Chun, Robert H.; Garzon, Maria C.; Holland, Kristen E.; Liberman, Leonardo; MacLellan-Tobert, Susan; Mancini, Anthony J.; Metry, Denise; Puttgen, Katherine B.; Seefeldt, Marcia; Sidbury, Robert; Ward, Kendra M.; Blei, Francine; Baselga, Eulalia; Cassidy, Laura; Darrow, David H.; Joachim, Shawna; Kwon, Eun Kyung M; Martin, Kari; Perkins, Jonathan; Siegel, Dawn H.; Boucek, Robert J.; Frieden, Ilona J.

In: Pediatrics, Vol. 131, No. 1, 01.2013, p. 128-140.

Research output: Contribution to journalArticle

Drolet, BA, Frommelt, PC, Chamlin, SL, Haggstrom, A, Bauman, NM, Chiu, YE, Chun, RH, Garzon, MC, Holland, KE, Liberman, L, MacLellan-Tobert, S, Mancini, AJ, Metry, D, Puttgen, KB, Seefeldt, M, Sidbury, R, Ward, KM, Blei, F, Baselga, E, Cassidy, L, Darrow, DH, Joachim, S, Kwon, EKM, Martin, K, Perkins, J, Siegel, DH, Boucek, RJ & Frieden, IJ 2013, 'Initiation and use of propranolol for infantile hemangioma: Report of a consensus conference', Pediatrics, vol. 131, no. 1, pp. 128-140. https://doi.org/10.1542/peds.2012-1691
Drolet, Beth A. ; Frommelt, Peter C. ; Chamlin, Sarah L. ; Haggstrom, Anita ; Bauman, Nancy M. ; Chiu, Yvonne E. ; Chun, Robert H. ; Garzon, Maria C. ; Holland, Kristen E. ; Liberman, Leonardo ; MacLellan-Tobert, Susan ; Mancini, Anthony J. ; Metry, Denise ; Puttgen, Katherine B. ; Seefeldt, Marcia ; Sidbury, Robert ; Ward, Kendra M. ; Blei, Francine ; Baselga, Eulalia ; Cassidy, Laura ; Darrow, David H. ; Joachim, Shawna ; Kwon, Eun Kyung M ; Martin, Kari ; Perkins, Jonathan ; Siegel, Dawn H. ; Boucek, Robert J. ; Frieden, Ilona J. / Initiation and use of propranolol for infantile hemangioma : Report of a consensus conference. In: Pediatrics. 2013 ; Vol. 131, No. 1. pp. 128-140.
@article{e6a24add6a19404b9397b27131f5dd6e,
title = "Initiation and use of propranolol for infantile hemangioma: Report of a consensus conference",
abstract = "Infantile hemangiomas (IHs) are common neoplasms composed of proliferating endothelial-like cells. Despite the relative frequency of IH and the potential severity of complications, there are currently no uniform guidelines for treatment. Although propranolol has rapidly been adopted, there is significant uncertainty and divergence of opinion regarding safety monitoring, dose escalation, and its use in PHACE syndrome (PHACE = posterior fossa, hemangioma, arterial lesions, cardiac abnormalities, eye abnormalities; a cutaneous neurovascular syndrome characterized by large, segmental hemangiomas of the head and neck along with congenital anomalies of the brain, heart, eyes and/or chest wall). A consensus conference was held on December 9, 2011. The multidisciplinary team reviewed existing data on the pharmacologic properties of propranolol and all published reports pertaining to the use of propranolol in pediatric patients. Workgroups were assigned specific topics to propose protocols on the following subjects: contraindications, special populations, pretreatment evaluation, dose escalation, and monitoring. Consensus protocols were recorded during the meeting and refined after the meeting. When appropriate, protocol clarifications and revision were made and agreed upon by the group via teleconference. Because of the absence of high-quality clinical research data, evidence-based recommendations are not possible at present. However, the team agreed on a number of recommendations that arose from a review of existing evidence, including when to treat complicated IH; contraindications and pretreatment evaluation protocols; propranolol use in PHACE syndrome; formulation, target dose, and frequency of propranolol; initiation of propranolol in infants; cardiovascular monitoring; ongoing monitoring; and prevention of hypoglycemia. Where there was considerable controversy, the more conservative approach was selected. We acknowledge that the recommendations are conservative in nature and anticipate that they will be revised as more data are made available.",
keywords = "Bradycardia, Hypertension, Hypoglycemia, Infantile hemangioma, PHACE syndrome, Propranolol",
author = "Drolet, {Beth A.} and Frommelt, {Peter C.} and Chamlin, {Sarah L.} and Anita Haggstrom and Bauman, {Nancy M.} and Chiu, {Yvonne E.} and Chun, {Robert H.} and Garzon, {Maria C.} and Holland, {Kristen E.} and Leonardo Liberman and Susan MacLellan-Tobert and Mancini, {Anthony J.} and Denise Metry and Puttgen, {Katherine B.} and Marcia Seefeldt and Robert Sidbury and Ward, {Kendra M.} and Francine Blei and Eulalia Baselga and Laura Cassidy and Darrow, {David H.} and Shawna Joachim and Kwon, {Eun Kyung M} and Kari Martin and Jonathan Perkins and Siegel, {Dawn H.} and Boucek, {Robert J.} and Frieden, {Ilona J.}",
year = "2013",
month = "1",
doi = "10.1542/peds.2012-1691",
language = "English",
volume = "131",
pages = "128--140",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "1",

}

TY - JOUR

T1 - Initiation and use of propranolol for infantile hemangioma

T2 - Report of a consensus conference

AU - Drolet, Beth A.

AU - Frommelt, Peter C.

AU - Chamlin, Sarah L.

AU - Haggstrom, Anita

AU - Bauman, Nancy M.

AU - Chiu, Yvonne E.

AU - Chun, Robert H.

AU - Garzon, Maria C.

AU - Holland, Kristen E.

AU - Liberman, Leonardo

AU - MacLellan-Tobert, Susan

AU - Mancini, Anthony J.

AU - Metry, Denise

AU - Puttgen, Katherine B.

AU - Seefeldt, Marcia

AU - Sidbury, Robert

AU - Ward, Kendra M.

AU - Blei, Francine

AU - Baselga, Eulalia

AU - Cassidy, Laura

AU - Darrow, David H.

AU - Joachim, Shawna

AU - Kwon, Eun Kyung M

AU - Martin, Kari

AU - Perkins, Jonathan

AU - Siegel, Dawn H.

AU - Boucek, Robert J.

AU - Frieden, Ilona J.

PY - 2013/1

Y1 - 2013/1

N2 - Infantile hemangiomas (IHs) are common neoplasms composed of proliferating endothelial-like cells. Despite the relative frequency of IH and the potential severity of complications, there are currently no uniform guidelines for treatment. Although propranolol has rapidly been adopted, there is significant uncertainty and divergence of opinion regarding safety monitoring, dose escalation, and its use in PHACE syndrome (PHACE = posterior fossa, hemangioma, arterial lesions, cardiac abnormalities, eye abnormalities; a cutaneous neurovascular syndrome characterized by large, segmental hemangiomas of the head and neck along with congenital anomalies of the brain, heart, eyes and/or chest wall). A consensus conference was held on December 9, 2011. The multidisciplinary team reviewed existing data on the pharmacologic properties of propranolol and all published reports pertaining to the use of propranolol in pediatric patients. Workgroups were assigned specific topics to propose protocols on the following subjects: contraindications, special populations, pretreatment evaluation, dose escalation, and monitoring. Consensus protocols were recorded during the meeting and refined after the meeting. When appropriate, protocol clarifications and revision were made and agreed upon by the group via teleconference. Because of the absence of high-quality clinical research data, evidence-based recommendations are not possible at present. However, the team agreed on a number of recommendations that arose from a review of existing evidence, including when to treat complicated IH; contraindications and pretreatment evaluation protocols; propranolol use in PHACE syndrome; formulation, target dose, and frequency of propranolol; initiation of propranolol in infants; cardiovascular monitoring; ongoing monitoring; and prevention of hypoglycemia. Where there was considerable controversy, the more conservative approach was selected. We acknowledge that the recommendations are conservative in nature and anticipate that they will be revised as more data are made available.

AB - Infantile hemangiomas (IHs) are common neoplasms composed of proliferating endothelial-like cells. Despite the relative frequency of IH and the potential severity of complications, there are currently no uniform guidelines for treatment. Although propranolol has rapidly been adopted, there is significant uncertainty and divergence of opinion regarding safety monitoring, dose escalation, and its use in PHACE syndrome (PHACE = posterior fossa, hemangioma, arterial lesions, cardiac abnormalities, eye abnormalities; a cutaneous neurovascular syndrome characterized by large, segmental hemangiomas of the head and neck along with congenital anomalies of the brain, heart, eyes and/or chest wall). A consensus conference was held on December 9, 2011. The multidisciplinary team reviewed existing data on the pharmacologic properties of propranolol and all published reports pertaining to the use of propranolol in pediatric patients. Workgroups were assigned specific topics to propose protocols on the following subjects: contraindications, special populations, pretreatment evaluation, dose escalation, and monitoring. Consensus protocols were recorded during the meeting and refined after the meeting. When appropriate, protocol clarifications and revision were made and agreed upon by the group via teleconference. Because of the absence of high-quality clinical research data, evidence-based recommendations are not possible at present. However, the team agreed on a number of recommendations that arose from a review of existing evidence, including when to treat complicated IH; contraindications and pretreatment evaluation protocols; propranolol use in PHACE syndrome; formulation, target dose, and frequency of propranolol; initiation of propranolol in infants; cardiovascular monitoring; ongoing monitoring; and prevention of hypoglycemia. Where there was considerable controversy, the more conservative approach was selected. We acknowledge that the recommendations are conservative in nature and anticipate that they will be revised as more data are made available.

KW - Bradycardia

KW - Hypertension

KW - Hypoglycemia

KW - Infantile hemangioma

KW - PHACE syndrome

KW - Propranolol

UR - http://www.scopus.com/inward/record.url?scp=84872283531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872283531&partnerID=8YFLogxK

U2 - 10.1542/peds.2012-1691

DO - 10.1542/peds.2012-1691

M3 - Article

C2 - 23266923

AN - SCOPUS:84872283531

VL - 131

SP - 128

EP - 140

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 1

ER -